Current and future trends in neoadjuvant immunotherapy for the treatment of triple-negative breast cancer.
| Autor: | de Mello RA; Department of Oncology, Oxford Cancer Center, Oxford University Hospitals NHS Foundation Trust, Churchill Hospital, OX3 7LE, Oxford, UK.; Department of Oncology, University of Oxford, OX3 7ER, Oxford, UK.; Post Graduation Program in Medicine, Faculty of Medicine, Nine of July University, 015250-000, São Paulo, Brazil., Perez KR; Post Graduation Program in Medicine, Faculty of Medicine, Nine of July University, 015250-000, São Paulo, Brazil.; Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru., Vazquez TP; São Paulo Cancer Institute, University of São Paulo, São Paulo, 01246-000, Brazil. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Immunotherapy [Immunotherapy] 2024 Mar; Vol. 16 (4), pp. 257-266. Date of Electronic Publication: 2024 Jan 10. |
| DOI: | 10.2217/imt-2022-0277 |
| Abstrakt: | Triple-negative breast cancer (TNBC) comprises 15-20% of all breast cancers (BC). Lacking targeted therapy options, TNBC becomes the focal point of clinical investigations aiming not only to identify drugs with enhanced response potential but also to uncover new immunological and/or metabolic pathways conducive to more effective treatments. Currently, neoadjuvant treatment for TNBC relies on standard chemotherapy in conjunction with immunotherapy, given the improved response observed with this drug combination. This review delves into the latest therapeutic updates in TNBC treatment and explores potential advancements shaping the future landscape of this disease in the neoadjuvant setting. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|